NASDAQ:AQST - Aquestive Therapeutics Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $6.13 -0.03 (-0.49 %) (As of 03/26/2019 04:00 PM ET)Previous Close$6.16Today's Range$5.99 - $6.6152-Week Range$5.60 - $20.70Volume51,000 shsAverage Volume115,948 shsMarket Capitalization$153.10 millionP/E Ratio-2.24Dividend YieldN/ABetaN/A ProfileDiscussionAnalyst RatingsChartEarningsInsider TradesInstitutional OwnershipHeadlinesSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Aquestive Therapeutics, Inc., a specialty pharmaceutical company, focuses on identifying, developing, and commercializing various products to address unmet medical needs. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; and Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery in the United States and internationally. Its proprietary product candidates comprise Libervant, a buccal soluble film formulation of diazepam for the treatment of recurrent epileptic seizures; and Exservan, an oral soluble film formulation of riluzole for the treatment of Amyotrophic Lateral Sclerosis. The company's proprietary pipeline of complex molecule products include AQST-108, a sublingual film formulation of epinephrine for the treatment of anaphylaxis; and AQST-305, a sublingual film formulation of octreotide for the treatment of acromegaly and neuroendocrine tumors. It also develops AQST-119, an oral soluble film formulation of tadalafil for the treatment of erectile dysfunction; and APL-130277, a sublingual film using apomorphine to treat parkinson's disease. Aquestive Therapeutics, Inc. was founded in 2004 and is headquartered in Warren, New Jersey. Receive AQST News and Ratings via Email Sign-up to receive the latest news and ratings for AQST and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:AQST Previous Symbol CUSIPN/A CIKN/A Webwww.aquestive.com Phone908-941-1900Debt Debt-to-Equity Ratio4.23 Current Ratio2.25 Quick Ratio2.09Price-To-Earnings Trailing P/E Ratio-2.24 Forward P/E Ratio-3.21 P/E GrowthN/A Sales & Book Value Annual Sales$67.43 million Price / Sales2.27 Cash FlowN/A Price / Cash FlowN/A Book Value$0.40 per share Price / Book15.33Profitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous Employees277 Outstanding Shares24,975,000Market Cap$153.10 million Next Earnings Date6/13/2019 (Estimated) OptionableNot Optionable Aquestive Therapeutics (NASDAQ:AQST) Frequently Asked Questions What is Aquestive Therapeutics' stock symbol? Aquestive Therapeutics trades on the NASDAQ under the ticker symbol "AQST." How were Aquestive Therapeutics' earnings last quarter? Aquestive Therapeutics Inc (NASDAQ:AQST) posted its quarterly earnings results on Thursday, March, 14th. The company reported ($0.56) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.91) by $0.35. The company earned $16.82 million during the quarter, compared to analyst estimates of $17.05 million. View Aquestive Therapeutics' Earnings History. When is Aquestive Therapeutics' next earnings date? Aquestive Therapeutics is scheduled to release their next quarterly earnings announcement on Thursday, June 13th 2019. View Earnings Estimates for Aquestive Therapeutics. What guidance has Aquestive Therapeutics issued on next quarter's earnings? Aquestive Therapeutics updated its FY 2019 earnings guidance on Thursday, March, 14th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $33-45 million, compared to the consensus revenue estimate of $48.62 million. What price target have analysts set for AQST? 5 Wall Street analysts have issued 1-year target prices for Aquestive Therapeutics' stock. Their predictions range from $14.00 to $30.00. On average, they anticipate Aquestive Therapeutics' share price to reach $23.60 in the next year. This suggests a possible upside of 285.0% from the stock's current price. View Analyst Price Targets for Aquestive Therapeutics. What is the consensus analysts' recommendation for Aquestive Therapeutics? 5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aquestive Therapeutics in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Aquestive Therapeutics. Has Aquestive Therapeutics been receiving favorable news coverage? Headlines about AQST stock have trended negative recently, InfoTrie Sentiment Analysis reports. The research firm identifies positive and negative press coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Aquestive Therapeutics earned a news impact score of -2.1 on InfoTrie's scale. They also assigned news coverage about the company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an effect on the company's share price in the near future. Who are some of Aquestive Therapeutics' key competitors? Some companies that are related to Aquestive Therapeutics include TG Therapeutics (TGTX), Synthorx (THOR), DiaMedica Therapeutics (DMCAF), ChemoCentryx (CCXI), Kura Oncology (KURA), Aurinia Pharmaceuticals (AUPH), Viking Therapeutics (VKTX), NuCana (NCNA), Obseva (OBSV), Evolus (EOLS), ProQR Therapeutics (PRQR), Crinetics Pharmaceuticals (CRNX), Odonate Therapeutics (ODT), GlycoMimetics (GLYC) and G1 Therapeutics (GTHX). What other stocks do shareholders of Aquestive Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Aquestive Therapeutics investors own include Aimmune Therapeutics (AIMT), Exelixis (EXEL), Portola Pharmaceuticals (PTLA), Alibaba Group (BABA), Johnson & Johnson (JNJ), Rigel Pharmaceuticals (RIGL), Progenics Pharmaceuticals (PGNX), Snap (SNAP), Amicus Therapeutics (FOLD) and Lexicon Pharmaceuticals (LXRX). Who are Aquestive Therapeutics' key executives? Aquestive Therapeutics' management team includes the folowing people: Mr. Keith J. Kendall, CEO, Pres & Director (Age 61)Mr. John T. Maxwell, Sr. VP & CFO (Age 54)Mr. Alexander Mark Schobel, Chief Innovation & Technology Officer (Age 60)Mr. Daniel Barber, Sr. VP and Chief Strategy & Devel. Officer (Age 43)Mr. Peter E. Boyd, Sr. VP of Operations & Value Delivery (Age 54) When did Aquestive Therapeutics IPO? (AQST) raised $60 million in an initial public offering (IPO) on Wednesday, July 25th 2018. The company issued 4,000,000 shares at a price of $14.00-$16.00 per share. BMO Capital Markets and RBC Capital Markets served as the underwriters for the IPO and Wedbush PacGrow and JMP Securities were co-managers. Who are Aquestive Therapeutics' major shareholders? Aquestive Therapeutics' stock is owned by many different of retail and institutional investors. Top institutional investors include Perceptive Advisors LLC (8.47%), BlackRock Inc. (2.57%), Massachusetts Financial Services Co. MA (1.90%), Bank of Montreal Can (0.48%), Geode Capital Management LLC (0.18%) and Geode Capital Management LLC (0.18%). Company insiders that own Aquestive Therapeutics stock include Alexander Mark Schobel, Daniel Barber, Douglas K Bratton, John T Maxwell, Keith J Kendall, Peter E Boyd and Theresa Wood. View Institutional Ownership Trends for Aquestive Therapeutics. Which institutional investors are buying Aquestive Therapeutics stock? AQST stock was bought by a variety of institutional investors in the last quarter, including Perceptive Advisors LLC, Massachusetts Financial Services Co. MA, BlackRock Inc., Bank of Montreal Can, Squarepoint Ops LLC, Millennium Management LLC, Geode Capital Management LLC and Geode Capital Management LLC. Company insiders that have bought Aquestive Therapeutics stock in the last two years include Alexander Mark Schobel, Daniel Barber, Douglas K Bratton, John T Maxwell, Keith J Kendall, Peter E Boyd and Theresa Wood. View Insider Buying and Selling for Aquestive Therapeutics. How do I buy shares of Aquestive Therapeutics? Shares of AQST can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Aquestive Therapeutics' stock price today? One share of AQST stock can currently be purchased for approximately $6.13. How big of a company is Aquestive Therapeutics? Aquestive Therapeutics has a market capitalization of $153.10 million and generates $67.43 million in revenue each year. The company earns $-61,380,000.00 in net income (profit) each year or ($2.80) on an earnings per share basis. Aquestive Therapeutics employs 277 workers across the globe. What is Aquestive Therapeutics' official website? The official website for Aquestive Therapeutics is http://www.aquestive.com. How can I contact Aquestive Therapeutics? Aquestive Therapeutics' mailing address is 30 TECHNOLOGY DRIVE, WARREN NJ, 07059. The company can be reached via phone at 908-941-1900 or via email at [email protected] MarketBeat Community Rating for Aquestive Therapeutics (NASDAQ AQST)Community Ranking: 2.3 out of 5 ( )Outperform Votes: 57 (Vote Outperform)Underperform Votes: 69 (Vote Underperform)Total Votes: 126MarketBeat's community ratings are surveys of what our community members think about Aquestive Therapeutics and other stocks. Vote "Outperform" if you believe AQST will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AQST will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 3/26/2019 by MarketBeat.com StaffFeatured Article: What are trading strategies for the 52-week high/low?